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Introduction 
In fetal rats, initial pituitary growth hormone (GH)
expression is detected on day 15 of gestation using a sen-
sitive method like the reverse transcriptase-polymerase
chain reaction (RT-PCR) [19]. In the following phase of
GH cell development there occurs expression of Pit-1, a
pituitary-specific transcriptional factor that mediates cell
proliferation and differentiation into specific hormone
producing cell types - thyrotropes, somatotropes or lac-
totropes [23]. During this period, the quantity of GH
transcripts remains at an extremely low level. A marked
increase in cell number and GH production occurs
between days 18 and 19 of fetal development [27]. After-
wards, during the perinatal period, the characteristically
high circulating GH level is the result of hypothalamo-
pituitary system immaturity [2,28]. 
It has been considered that pituitary GH promotes
and controls fetal development and body weight by
stimulating the family of hepatic growth factors. Recent
investigations showed that extrapituitary GH as well as
local production of growth factors had great
paracrine/autocrine influence on fetal developmental
processes and differentiation. Expression of GH and GH
receptor in a wide variety of tissues is established before
the pituitary gland and circulatory system becomes
functional [21,30]. In rats and mice a contribution of
pituitary GH to growth, development and body weight
has been demonstrated during the second week of life
i.e. postnatally [18]. The influence of pituitary GH on
normal growth and body weight in near-term fetuses,
immediately after the GH cells become functional, is
still difficult to understand and not well defined. 
Adrenal glucocorticoids also have a powerful
influence on growth, maturation and tissue remodel-
ing during fetal development. Glucocorticoids accel-
erate the maturation of numerous organs essential for
the maintenance of homeostasis immediately after
birth [3,20]. In addition, glucocorticoids are indis-
pensable for proper differentiation, expansion and
function of certain pituitary cell lineages, especially
GH cells [12,16]. 
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Abstract: Growth hormone (GH) and glucocorticoids have a powerful influence on controlling fetal growth, differentiation
and maturation of numerous tissues. In the present study, the effect of maternal dexamethasone (Dx) treatment on GH cells
and body weight in 19- and 21-day-old rat fetuses was investigated using immunocytochemical and morphometric methods.
Pregnant female rats received daily injections of 1.0-0.5-0.5 mg Dx/kg b.w. on days 16-18 of pregnancy (experimental
group), while the control group received an equal volume of saline. Dx treatment of pregnant rats enhanced immunostain-
ing intensity and significantly increased (p<0.05) GH nuclear and cell volume, as well as volume density and number of GH
cells per square millimeter in 19-day-old fetuses compared to the controls. In 21-day-old fetuses after maternal Dx admin-
istration, immunoreactivity, volume density and number of GH cells remained significantly increased (p<0.05). Dx treat-
ment of pregnant rats resulted in marked body weight reduction of 21-day-old but not 19 days old fetuses in comparison
with the corresponding controls. The presented results demonstrate that maternal Dx application has pronounced effect on
morphometric parameters of GH cells of 19- and 21-day-old fetuses. Also, in near-term rat fetuses body weight was large-
ly independent of pituitary GH cell activity. 
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The aim of our investigations was to assess the
influence of Dx treatment of gravid females on mor-
phometric parameters of pituitary GH cells and body
weight in near-term fetuses and to examine the rela-
tionship between histological appearance and morpho-
metric characteristics of pituitary GH cells and body
weight in 19- and 21-day-old control fetuses and fetus-
es after maternal Dx administration. 
Materials and methods
Animal treatment. Female and male Wistar strain rats, weigh-
ing approximately 250 and 400 g, respectively, were mated in
the laboratory of the Institute for Biological Research, Belgrade,
during the night. The morning on which sperm positive smears
were obtained was declared gestation day 1. Pregnant females were
housed individually under standard conditions (12:12 h light-dark
cycle at 22 ± 2°C) and offered food and water ad libitum. On 16th
day of pregnancy dams received subcutaneously 1.0 mg Dx/kg
b.w., followed by 0.5 mg Dx/ kg b.w./day on 17th and 18th days of
gestation. The control gravid females received the same volume of
saline vehicle. On days 19 and 21 of gestation the rats were killed
under ether anesthesia and the fetuses were removed and prepared
for histological and morphometric measurements. 
Experimental protocols were approved by the Local Animal
Care Committee and conformed to the recommendations given in
"Guide for the Care and Use of Laboratory Animals" (National
Academy Press, Washington D.C., 1996).
Light microscopy and immunocytochemistry. The pituitary
glands, with part of the sphenoid bone or fetal heads, were excised
and fixed in Bouin's solution for 48 h and embedded in paraffin.
Three pituitary sections from the dorsal, medial and ventral parts,
5-μm thick, were deparaffinized in xylol and rehydrated in
decreasing concentrations of ethanol before preparation for
immunocytochemical staining. 
Pituitary GH was localized immunocytochemically using the
peroxidase-antiperoxidase complex (PAP) method of Sternberger
[26]. Endogenous peroxidase activity was blocked by incubation in
9 mM hydrogen peroxide solution in methanol for 30 min at ambi-
ent temperature. Before application of specific primary antibodies,
nonspecific background staining was prevented by incubation of
the sections with normal nonimmune porcine serum diluted in
phosphate-buffered saline (PBS; pH=7.4) for 60 min. Sections
were then overlaid with the appropriate dilution (1:300) of specif-
ic rabbit anti-human GH antibodies (Dako, Glostrup, Denmark) for
24 h at room temperature [11]. After washing in PBS, sections
were incubated for 60 min with the secondary antibody (swine-
anti-rabbit IgG; Dako) for 45 min, rinsed again with PBS for 10
min and then incubated with rabbit PAP complex for 45 min. Anti-
body localization was visualized by immersing the sections in Tris-
HCl-buffered saline (0.5 mol/l; pH=7.4) supplemented with 0.05%
3,3-diaminobenzidine tetrachloride (DAB; Serva, Heidelberg, Ger-
many) and 9 mM hydrogen peroxide. Sections were thoroughly
washed under running tap water, counterstained with hematoxylin
and mounted in Canada balsam (Alkaloid, Skopje, Macedonia).
Morphometry. Volume densities (Vv) of the nuclei and cytoplasm
of GH-immunopositive cells as well as the numerical density (Na)
of their nuclei per μm3 were measured in 50 test areas on each of
three pituitary sections per pituitary gland, per fetus, at a magnifi-
cation of 1000 ×, using the M42 multipurpose test system [31]. 
The number of nuclei of immunostained GH-producing cells
was estimated using the formula of Weibel [31]. Since rat GH-
positive cells are mononuclear, the numerical density of nuclei
(Nv) corresponded to the number of cells per mm3, according to the
formula: 
Nv = (k/β) × (Na3/2/Vv1/2)
On the basis of earlier karyometric studies, the shape coeffi-
cient β for pituitary cells was estimated to be 1.382 [9]. This
relates Nv (number of cells counted per unit volume) to Na
(number of cells counted per mm2) and Vv (volume density) and
depends on the axial ratio of nuclei. The volume density of GH-
positive cells was expressed as a percentage of total pituitary
cell volume.
Digital images were made using a Leica DM RB Photo Micro-
scope (Leica, Wetzlar, Germany) equipped with a JVC TK 1280E
Video Camera (Leica). Qwin software (Leica) was employed for
the acquisition and analysis of the images.
Statistical analysis. All results were expressed as means for eight
to ten animals per group ± SD. Data were tested for normality of
distribution by the Kolmogorov-Smirnov test, whereas the homo-
geneity of variances was evaluated by the F-test. Student's t-test
was used to compare the mean values. The minimum level of sta-
tistical significance was set at p<0.05. 
Results
Histological analysis
In near-term fetuses, immunoreactive GH-producing
cells of the anterior pituitary gland were usually
rounded or ellipsoid. Immunopositive cells were scat-
tered throughout the anterior lobe in both control
groups. In 19-day-old fetuses, the intensity of staining
varied between cells: numerous GH cells were weakly
immunoreactive, while only a few GH cells showed
intense immunostaining. After 48 h, GH cells became
well differentiated with the characteristic cytoplasmat-
ic ring-shaped area around the nuclei. Histological
analysis also showed that the intensity of GH cell
immunostaining increased throughout the duration of
the examined period. An apparent increase in fetal GH
cell number was seen in control fetuses from day 19 to
day 21 of pregnancy (Fig. 1A and C).
All the examined 19-day-old fetuses from Dx-treat-
ed females had well differentiated GH cells at this stage
of development with typical intensely, dark cytoplas-
mic staining around centrally located nuclei. The num-
ber and size of immunoreactive GH cells was increased
24 h after Dx treatment of gravid females in compari-
son with the corresponding control fetuses. The GH
cells were evenly distributed throughout the gland with
infrequent cluster formation. This increase in number
and immunoreactivity of GH cells remained even 72 h
after Dx application i.e. in 21-day-old fetuses com-
pared with the control group (Fig. 1B and D). 
Morphometric parameters 
Morphometric parameters such as GH nuclear and cell
volume, volume density and number of GH cells per unit
area markedly increased in parallel with fetal develop-
ment i.e. from gestational days 19 to 21 (Fig. 2). 
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Dx treatment of pregnant rats resulted in significant
increases in GH nuclear and cell volume in their 19-
day-old fetuses, by 36% and 15%, respectively. The
volume density as well as the number of fetal GH cells
per square millimeter also showed a significant
increase after maternal Dx administration when com-
pared with 19-day-old control fetuses. 
In 21-day-old fetuses, 72 hours after the last Dx
application significantly higher values for GH cell vol-
ume density and their number per square millimeter
were still observed in comparison with the correspon-
ding control group. There were no significant differ-
ences for the GH nuclear and cell volumes between the
experimental and control fetuses (Fig. 2). 
Body weight
The body weights gradually increased in near-term con-
trol fetuses. Maternal exposure to Dx during days 16-18
of pregnancy did not affect the body weights of 19-day-
old fetuses, but a significant reduction of body weight
(24%) was noticed in 21-day-old fetuses in comparison
with the corresponding control fetuses (Table 1).
Discussion
The present study demonstrated that maternal Dx
administration did exert a stimulatory effect on all
examined morphometric parameters of GH cells in the
19-day-old fetuses, and significant increases in volume
density and number of GH cells per unit area remained
in 21-day-old fetuses. Nevertheless, multiple Dx treat-
ment of pregnant rats resulted in a significant reduc-
tion in body weight of 21-day-old but not 19 days old
fetuses. 
The marked increase in immunocytochemically
labeled GH nuclear and cell volume from days 19 to
21 of fetal development was accompanied by a sig-
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Fig. 1. Pituitary GH cells of control and experimental fetuses. A. Pituitary GH cells of control 19-day-old fetuses. Bar = 20 μm. B. Strong
immunostaining of GH cells after maternal Dx treatment in 19-day-old fetuses. Bar = 20 μm. C. GH cells of control 21-day-old fetuses.
Bar = 20 μm. D. Increased immunoreactivity and number of GH cells in 21-day-old fetuses after maternal Dx administration. Bar = 20 μm.
Insets bar = 8 μm. Arrows: immunocytochemically labeled GH cells. 
nificant rise in volume density as well as in the num-
ber of GH cells per square millimeter. Morphometric
measurement and histological analysis have demon-
strated that fetal GH cells start to produce significant
amounts of GH after day 19 of pregnancy, and devel-
op into functional GH cells. These results are in agree-
ment with the finding that pituitary GH content
increased 58-fold from days 19 to 21 of fetal develop-
ment [19]. The significant increase in the number of
GH cells throughout the examined period might be
explained by the findings of Taniguchi et al. [27].
These authors observed the first mitoses of
immunopositive GH cells immediately after their
appearance in the pituitary - on 19th fetal day. During
subsequent days, numerous differentiated GH cells
continue to proliferate thus forming the predominant
subpopulation of all hormone-producing cells in the
perinatal period [27]. 
Between days 18 and 19 of gestation, fetal GH cells
appear spontaneously in parallel with the peak of activ-
ity of the fetal pituitary-adrenal system, i.e. with the
increased glucocorticoid level in the fetal circulation
[29]. Subsequent rapid functional maturation and the
increase in the number of GH cells were associated with
further rise in corticosterone during the last days of
intrauterine development, demonstrating the indispen-
sable role of circulating corticosteroids in GH cell onset
and development [17,22]. On the contrary, decreased
fetal circulating corticosterone due to metyrapone appli-
cation significantly reduced the number of GH cells in
the fetuses on day 19 of pregnancy [15]. 
Glucocorticoid passage through the placenta is high-
ly controlled by the placental enzyme 11β-hydroxys-
teroid-dehydrogenase-II (11βHSD-II), which inacti-
vates maternal corticosteroids to inert forms. Due to
11βSD-II activity, fetal glucocorticoid levels are much
lower than maternal concentrations. Nevertheless, Dx
treatment of gravid females affects fetuses, since Dx is
a synthetic glucocorticoid that easily passes across the
placenta, avoiding the enzymatic barrier, and reaches
the fetal circulation [24]. In our 19-day-old fetuses, the
elevated level of circulating corticosteroids induced the
advanced histological appearance and increased size of
GH cells in comparison to the controls. The enhanced
immunostaining intensity and GH nuclear and cell vol-
ume appear to be the result of increased GH synthesis
and storage in individual cells after maternal Dx expo-
sure. Dx and corticosterone, the major circulating glu-
cocorticoid in rats, were able to induce dose-dependent
increases in GH mRNA in vivo [15] and in vitro within
24 h [13]. Moreover, Dx increased the percentage of
total pituitary cells that secreted GH [17]. 
It has been established that the primary site of glu-
cocorticoid action is the pituitary gland [13]. Gluco-
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Fig. 2. Morphometric parameters of 19- and 21-day-old fetal GH cells after maternal treatment with Dx (Dx) - experimental group or
saline-administered (C) - control group. A. Volume of GH cell nuclei. B. Volume of GH cells. C. Volume density of GH cells. D. Num-
ber of GH cells per unit area. Results are presented as means   ±SD (n = 8); * p<0.05 vs. C; a p<0.05 vs. 19-day-old C. 
corticoid receptor (GR) mRNA was detected in the ade-
nohypophysis on 13th day of fetal development, and the
intensity of the mRNA signal continuously increased
from that time [5]. Increases in the number of fetal GH
cells expressing GR between 17th and 18th days were
confirmed by the results of immunocytochemical studies
[14]. GR, acting as a transcriptional activator, is able to
mediate glucocorticoid action, including Dx, during the
fetal period of life, and therefore its appearance repre-
sents an important step in GH cell maturation. 
Hypothalamic GH-releasing hormone (GHRH), a
hypothalamic polypeptide, has a stimulatory effect on
GH release and proliferation of pituitary GH cells.
GHRH may play an active role in controlling the function
of GH cells during the last few days of pregnancy [6]. The
binding of GHRH to the pituitary GHRH receptor is an
essential condition for the GH cell to respond in a regu-
lated manner. Dx induced GHRH receptor mRNA
expression and accumulation in the fetal rat pituitary
gland [14] amplified the stimulatory influence of GHRH.
As a consequence, Dx induced GH cells to synthesize and
release more GH, leading to increases in GH cell size
(nuclear and cell volume) as established in this work. 
The present results demonstrate increased volume
density and number of GH cells per square millimeter in
19-day-old experimental fetuses compared to control
fetuses. Maternal Dx treatment induced the appearance
of numerous immunopositive fetal GH cells, initiating
and accelerating GH mRNA synthesis in immature GH
cells, operating by an unidentified factor [16]. It was
established that this factor is not Pit-1, which is known
to be required for GH gene expression [13]. Corticos-
terone-induced GH cell differentiation involves GH
expression in cells not expressing GH mRNA previous-
ly [17]. Moreover, Dx can induce GH progenitors to
start GH synthesis one day earlier than in normal fetus-
es. In vitro findings suggested that incubation of pitu-
itary gland with Dx for 24 h increased GH mRNA on
fetal day 18 to a level nearly identical to that in intact
19-day-old fetuses [13]. The numerous de novo differ-
entiated GH cells provoked by Dx treatment in 19-day-
old fetuses represent a larger pool for further prolifera-
tion. During the next 48 h, from days 19 to 21 of fetal
development, more GH cells underwent division in the
experimental group than in the control group. A signifi-
cant increase in GH cell number and volume density
compared to the controls remained in 21-day-old fetus-
es after maternal Dx exposure. Increased GH cell num-
ber demonstrated by morphometry was also visible dur-
ing microscopic examination of histological sections. 
As mentioned before, functional status of fetal adre-
nal glands has a great impact on GH cell development.
In 19-day-old fetuses, corticosterone production was not
decreased by maternal Dx treatment, meaning that level
of circulating corticosteroids of fetal origin was not
altered under Dx influence [10]. At the same time, both
size and number of GH cells were increased after expo-
sure of gravid females to Dx. In 21-day-old fetuses an
opposite situation occurred. Maternal Dx treatment sig-
nificantly inhibited steroidogenesis in the inner zone of
adrenal gland cortex, responsible for glucocorticoid
synthesis, which led to marked decline in blood gluco-
corticoid level [4]. Taking into consideration that Dx
concentration decreased in the fetal circulation with
advancing fetal age, its stimulatory effect on GH cells
declined, too. Therefore, significant differences in vol-
umes of GH cells and nuclei between experimental and
control groups disappeared 72 h after the last Dx dose.  
There were no significant differences in body weight
between control and experimental 19-day-old fetuses.
However, marked intrauterine growth retardation due to
maternal Dx exposure throughout gestation becomes
visible in 21-day-old fetuses. As a rapidly growing and
short gestation species, pregnancy in rats lasts for 22
days. The last third is a critical developmental stage
when organogenesis and differentiation take place and
at the same time represents the most vulnerable period
for inducing changes [1]. By accelerating organization-
al events and maturation of the organs [7], Dx induced
fetal weight loss 72 h after the last dose. Current results
show that the most intensive increase in fetal body
weight occurs from day 19 to 21 of gestation when a
progressive 2.6-fold rise in body weight has been estab-
lished. Dx applied for three days during the last
trimester of pregnancy led to interruption of the rapid
fetal growth near-term and consequently the most
notable weight reduction occurred in 21-day-old fetuses
or immediately before term. Several studies in humans
as well as in animals have demonstrated that fetal expo-
sure to glucocorticoid excess induces intrauterine
growth retardation [24,25]. It is also acknowledged that
glucocorticoid treatment during pregnancy reduces birth
weight that may persist postnatally in humans, non
human primates and rodents. The precise effects on
body weight changes depend on the dose used and its
timing during pregnancy [8]. 
The present results confirm that maternal Dx
treatment from days 16 to 18 of pregnancy can influ-
ence in different direction morphometric characteris-
tics of pituitary GH cells and body weight in 19- and
21-day-old fetuses. Dx exerted stimulatory influence
on immunoreactivity, size and number (morphometric
parameters) of pituitary GH cell in near-term fetuses. At
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Table 1. Influence of maternal Dx administration on body weight
in near-term fetuses
Results are given as means ±SD (n = 8); * p<0.05 vs. C; a p<0.05 vs. 
19-day-old C.
the same time, after maternal Dx exposure body weight
was not significantly changed in 19-day-old fetuses and
then marked weight loss occurred in 21-day-old fetuses
compared to controls. It might be concluded that during
the last days of pregnancy pituitary GH cell activity did
not control fetal body weight. 
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